Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRACE: VMAT-SIB + XELOX in Rectal Cancer
NCT02745639Phase 2Completed
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- Feb 2010
- Primary completion
- Nov 2013
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
01
Overview
A Phase 2 trial of oxaliplatin, capecitabine in rectal cancer, sponsored by Sant'Orsola-Malpighi University Hospital. Started Feb 2010; status: completed.
02
Drugs
oxaliplatincapecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT02745639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02745639.